Kura Oncology, Inc. (Kura)

Oncology Corporate Profile

HQ Location

11119 North Torrey Pines Road, Suite 125
La Jolla, CA 92037

Company Description

Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura Oncology's diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology's approach to drug development is focused on rapidly translating novel science into life-saving medicines

Website: http://www.kuraoncology.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
tipifarnibfarnesyl transferase inhibitorsUrothelial carcinomaII
tipifarnibfarnesyl transferase inhibitorsT-cell LymphomaI
KO-947ERK inhibitorMelanomaPreclinical
KO-947ERK inhibitorNon Small Cell Lung Cancer (NSCLC)Preclinical
KO-947ERK inhibitorPancreatic cancerPreclinical

View additional information on product candidates here »

Source


http://www.kuraoncology.com/

Recent News Headlines

Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results

3/14/2017 08:00 pm

[GlobeNewswire] - LA JOLLA, Calif., March 14, 2017-- Kura Oncology, Inc., a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported fourth quarter and full ...

Kura Oncology to Report Fourth Quarter and Full Year 2016 Financial Results

3/7/2017 09:00 pm

[GlobeNewswire] - LA JOLLA, Calif., March 07, 2017-- Kura Oncology, Inc., a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth ...

Kura Oncology Reports Updated Clinical Activity Data in Ongoing Phase 2 Trial for Tipifarnib

3/6/2017 12:03 pm

[GlobeNewswire] - LA JOLLA, Calif., March 06, 2017-- Kura Oncology, Inc., a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced updated results from the ...

Kura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017

2/27/2017 12:03 pm

[GlobeNewswire] - LA JOLLA, Calif., Feb. 27, 2017-- Kura Oncology, Inc., a clinical stage biopharmaceutical company, today announced an oral presentation for its lead product candidate, tipifarnib, at the 15 th International ...

Kura Oncology to Participate in Three Upcoming Investor Conferences

2/9/2017 09:00 pm

[GlobeNewswire] - LA JOLLA, Calif., Feb. 09, 2017-- Kura Oncology, Inc., a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to ...

Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia

1/17/2017 12:03 pm

[GlobeNewswire] - LA JOLLA, Calif., Jan. 17, 2017-- Kura Oncology, Inc., a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase 2 clinical trial of tipifarnib in patients ...

Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 and Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program

1/4/2017 01:03 pm

[at noodls] - LA JOLLA, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) accepted ...

Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 and Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program

1/4/2017 12:03 pm

[GlobeNewswire] - LA JOLLA, Calif., Jan. 04, 2017-- Kura Oncology, Inc., a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration accepted the company’ s Investigational New ...

Kura Oncology Appoints Steven Stein, M.D. to Board of Directors

1/3/2017 09:02 pm

[at noodls] - LA JOLLA, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced the appointment of Steven H. Stein, M.D., to its board ...

Kura Oncology Appoints Steven Stein, M.D. to Board of Directors

1/3/2017 09:00 pm

[GlobeNewswire] - LA JOLLA, Calif., Jan. 03, 2017-- Kura Oncology, Inc., a clinical stage biopharmaceutical company, today announced the appointment of Steven H. Stein, M.D., to its board of directors. Stein currently serves ...